Urinary trypsin inhibitor reduced neointimal hyperplasia induced by systemic inflammation after balloon injury in rabbits

Inflammation Research

Volumn 62, Issue 2, 2013, Pages 173-179

  Kong, Junying ^a   Zhang, Jian ^a   Li, Lin ^a   Jiang, Guihua ^a   Wang, Xinchun ^a   Liu, Xiaojun ^a   Yu, Bo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Inflammatory response; Neointimal hyperplasia; Restenosis

Indexed keywords

INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ILIAC ARTERY OBSTRUCTION; INFLAMMATION; MALE; MORPHOMETRICS; NEOINTIMA TO MEDIA RATIO; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABBIT; SYSTEMIC INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATHETERIZATION; GLYCOPROTEINS; HYPERPLASIA; ILIAC ARTERY; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; NEOINTIMA; RABBITS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873686806     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0568-x     Document Type: Article

References (36)

1. Serrano CV Jr, Ramires JA, Venturinelli M, Arie S, D'Amico E, Zweier JL, Pileggi F, da Luz PL. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecules expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29:1276-83.
2. Hancock WW, Adams DH, Wyner LR, Sayegh MH, Karnovsky MJ. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol. 1994;145:1008-14.
3. Welt FG, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol. 2000;20:2553-8.
4. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation. 1995;92:2995-3005.
5. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104:2228-35.
6. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-11.
7. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-45.
8. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(Suppl III):III47-52.
9. Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, Sluiter W. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320-5.
10. Moreno PR, Bernardi VH, López-Cuéllar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation. 1996;94:3098-102.
11. Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ, von Beckerath N, Böttiger C, Duff GW, Schömig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000;36:2168-73.
12. Rogers C, Edelman ER, Simon DI. A mAb to the β2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95:10134-9.
13. Lin SD, Endo R, Sato A, Takikawa Y, Shirakawa K, Suzuki K. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J Gastroenterol Hepatol. 2002;17:140-7.
14. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol. 2001;69:241-7.
15. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001;15:101-5.
16. Ambiru S, Miyazaki M, Sasada K, Ito H, Kimura F, Nakagawa K, Shimizu H, Ando K, Nakajima N. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig Surg. 2000;17:337-43.
17. Damas P, Canivet JL, de Groote D, Vrindts Y, Albert A, Franchimont P, et al. Sepsis and serum cytokine concentrations. Crit Care Med. 1997;25:405-12.
18. Tani T, Abe H, Endo Y, Hanasawa K, Kodama M. Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. Am J Surg. 1998;175:142-5.
19. Sato N, Murakami K, Ishida K, Ikeda K, Saito K. Pulmonary hypertension and polymorphonuclear leukocyte elastase after esophageal cancer operations. Ann Thorac Surg. 1991;51:754-8.
20. Akashi K, Ishimaru T, Shibuya T, Harada M, Niho Y. Human urinary proteinase inhibitor in the treatment of P carinii pneumonia. Chest. 1991;99:1055-6.
21. Jiang YF, Wang WW, Ye WL, Ni YF, Li J, Chen XL, Jin SW, Lian QQ. Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases. Zhonghua Yi Xue Za Zhi. 2008;88:2893-7.
22. Zhou Q, Wang G, Gao C, Chen T. Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:107-10.
23. Epstein H, Grad E, Golomb M, Koroukhov N, Edelman ER, Golomb G, Danenberg HD. Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis. 2008;199:41-6.
24. Danenberg HD, Welt FGP, Walker M III, Seifert P, Toegel GS, Edelman ER. Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation. 2002;105:2917-22.
25. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotide to the P65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prvent neointima formation in rat carotid arteries. Biochem Biophys Res Commun. 1995;213:827-36.
26. Gogo PB Jr, Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis. 2005;19:87-92.
27. Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1996;28:1127-33.
28. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327-34.
29. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34(5):1512-21.
30. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H, Miyazaki S. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000;181:1101-9.
31. Nishijima J, Hiraoka N, Murata A, Oka Y, Kitagawa K, Tanaka N, Toda H, Mori T. Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukoc Biol. 1992;52:262-8.
32. Bingyang J, Jinping L, Mingzheng L, Guyan W, Zhengyi F. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularization: effect of ulinastatin on inflammatory response. J Cardiovasc Surg. 2007;48:497-503.
33. Gao C, Huan J, Li W, Tang J. Protective effects of ulinastatin on pancreatic and renal damage in rats following early scald injury. Burns. 2009;35:547-52.
34. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation. 2001;104:860-3.
35. Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006;91:847-51.
36. Nishiyama SN, Hatai Y, Asano Y, Obayashi T, Takeshita S, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Kanai MT, Ishiwata T, Kobayashi T, Sato H, Takizawa M. With Kawasaki disease: a retrospective study ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients. Circulation. 2011;124:2822-8.